

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 5 February 2004 (05.02.2004)

PCT

(10) International Publication Number WO 2004/011622 A3

(51) International Patent Classification7: C12N 5/06, 5/08

(21) International Application Number:

PCT/US2003/023869

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/399,493

30 July 2002 (30.07.2002) US

(71) Applicant (for all designated States except US): MASS-ACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02173 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEACH, John, K. [US/US]; 328 Commercial Street #22. Boston, MA 02109 (US). TANNENBAUM, Steven, R. [US/US]; 15 Bent Hill Drive, Framingham, MA 01701 (US).

(74) Agents: EISENSTEIN, Ronald, I. et al.; Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110-2131 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 26 August 2004

For two-letter codes and other abbreviations, refer to the "Guidunce Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PERFUSION AND PLATING OF PRIMARY HEPATOCYTES AND A MEDIUM THEREFORE

(57) Abstract: The present invention provides methods for culturing primary hepatocytes with improved long term function and improved viability, by plating the hepatocytes in the presence of an anti-oxidants) as well as an agent(s) which is a functional inhibitor of enzymes that generate reactive oxygen and reactive nitrogen species. One preferred embodiment provides a combination of 2-oxothizolidine and tocopherol succinate. Another preferred embodiment provides a combination of N^G-methylarginine and mannitol.

From the INTERNATIONAL SEARCHING AUTHORITY

international search report.

To: RONALD I. EISENSTEIN NIXON PEABODY LLP NOTIFICATION OF TRANSMITTAL OF 101 FEDERAL STREET THE INTERNATIONAL SEARCH REPORT BOSTON, MA 02110 OR THE DECLARATION (PCT Rule 44.1) 06 JUL 2004 Date of Mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION See paragraphs 1 and 4 below 019028-05287 International filing date International application No. (day/month/year) PCT/US03/23869 30 July 2003 (30.07.2003) Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY The applicant is hereby notified that the international search report has been established and is transmitted herewith. \bowtie Filing of amendments and statement under Article 19:

Where? Directly to the International Bureau of WIPO, 34, chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

The time limit for filing such amendments is normally two months from the date of transmittal of the

4. Reminders

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230

Telephone No. 571/272-1600

Form PCT/ISA/220 (April 2002)

(See notes on accompanying sheet)

PCT


INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or age 019028-05287	nt's file reference	FOR FURTHER ACTION		cation of Transmittal of International Search Report T/ISA/220) as well as, where applicable, item 5
International appli PCT/US03/23869	cation No.	International filing date (day/mon 30 July 2003 (30.07.2003)	nth/year)	(Earliest) Priority Date (day/month/year) 30 July 2002 (30.07.2002)
Applicant MASSACHUSET	rs institute of te	CHNOLOGY		
This international applicant according	search report has been g to Article 18. A co	n prepared by this International S py is being transmitted to the Int	earching A	Authority and is transmitted to the Bureau.
This international	search report consists It is also accompanied	of a total of sheets. I by a copy of each prior art docu	ıment cited	d in this report.
Basis of the R a. With relanguage	gard to the language,	the international search was carried, unless otherwise indicated under	d out on the this item.	e basis of the international application in the
Auth b. With re	ority (Rule 23.1(b)). gard to any nucleotide			e international application furnished to this ne international application, the international
conta	ined in the internationa	l application in written form.		·
filed	together with the interr	national application in computer re	adable for	m.
furni	shed subsequently to th	is Authority in written form.		
furni	shed subsequently to th	is Authority in computer readable	form.	77
		uently furnished written sequence Iled has been furnished.	listing doe	es not go beyond the disclosure in the
	atement that the inform furnished.	nation recorded in computer readal	ole form is	identical to the written sequence listing has
2. Certa	in claims were found	unsearchable (See Box I).		
	of invention is lackin	g (See Box II).		
4. With regard t				·
=	xt is approved as subm	• • • • • • • • • • • • • • • • • • • •		
the te	xt has been established	by this Authority to read as follow	ws:	
5. With regard to	the abstract,			
	xt is approved as submi	itted by the applicant.		
the te	xt has been established, within one month from	according to Rule 38.2(b), by thi		y as it appears in Box III. The applicant ch report, submit comments to this
6. The figure of	the drawings to be pub	lished with the abstract is Figure l	No	5-7
as sug	gested by the applicant			None of the figures
becau	se the applicant failed t	o suggest a figure.		
becau	se this figure better cha	racterizes the invention.		

Form PCT/ISA/210 (first sheet) (July 1998)





International application No.

PCT/US03/23869

A. C IPC(7)	LASSIFICATION OF SUBJECT MATTER : C12N 5/06, 5/08		
US CL	: 435/383, 366		
	g to International Patent Classification (IPC) or to both	national classification and IPC	
	ELDS SEARCHED	11 1 (6.2)	
	documentation searched (classification system follower: 435/383, 366	d by classification symbols)	
Documen	tation searched other than minimum documentation to t	the extent that such documents are included	d in the fields searched
	c data base consulted during the international search (na e Continuation Sheet	ame of data base and, where practicable, s	earch terms used)
C. DO	DCUMENTS CONSIDERED TO BE RELEVANT		
Category			Relevant to claim No.
Y	US 5,198,432 A(FARISS) 30 March 1993 (30.03.	1993), column 13, lines 10-25.	1-8
Y	ROBERTS et al. Prodrugs of L-Cysteine as Protect Induced Hepatotoxicuty. 2-(Polyhydroxyalkyl)-and carboxylic Acids. Journal of Medicinal Chemistry 1896, especially abstract.	d 2-(Polyhydroxyalkyl)thiazolidine-4(r)-	1-8
Y	DILWORTH et al. Spntaneous Nitric Oxide in He Compound-Induced Apoptosis. Toxicology in Vitr pages 623-630, especialy abstact.	patocyte Monolayers and Inhibition of o. December 2001, Vol 15, No. 6,	1-8
Y	POURAHMAD et al. A Comparison of Hepatocyt Cd2+. Toxicology. March 2000, Vol 143, No. 3,		1-8
Furt	ner documents are listed in the continuation of Box C.	See patent family annex.	·
*	Special categories of cited documents:	"T" later document published after the inte date and not in conflict with the applic	
	ent defining the general state of the art which is not considered to be icular relevance	principle or theory underlying the inve	ntion
"E" earlier	application or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone	elaimed invention cannot be ed to involve an inventive step
	ent which may throw doubts on priority claim(s) or which is cited to the the publication date of another citation or other special reason (as ed)	"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is
"O" docum	ent referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	
	ent published prior to the international filing date but later than the \prime date claimed	"&" document member of the same patent i	amily
Date of the	actual completion of the international search	Date of mailing of the international sear	ch report
	2004 (19.03.2004)	06	JUL EUNA
M C	mailing address of the ISA/US Lail Stop PCT, Attn: ISA/US commissioner for Patents	Authorized officer Bell /	JUL 2004
Α	O. Box 1450 lexandria, Virginia 22313-1450 No. (703)305-3230	Telephone No. 571/272-1600	0



PCT/US. 869	

		•	
Continuation of B. FIELDS SEARCHI	FD Itom 3:		
WEST LISPT, DWPI: STN: BIOSIS, CAPL	US, MEDLINE		
WEST USPT, DWPI; STN: BIOSIS, CAPLUsearcg terms: hepatocytes, anti-oxidant, toco	pherol succinate, mannitol, nitric or	xide, methylaraginine, oxo-thiazolidine	
	-		
	-		
	-		
	-		
	-		
	-		
	-		
*	-		
*	-		
	-		
	-		
	-		
	_		
	-		
	-		
	-		
	-		
	-		
	-		

Form PCT/ISA/210 (second sheet) (July 1998)





NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/23869

	SSIFICATION OF SUBJECT MATTER		
IPC(7) US CL	: C12N 5/06, 5/08 : 435/383, 366		
According to	International Patent Classification (IPC) or to both	national classification and IPC	
	DS SEARCHED		
	ocumentation searched (classification system followed 35/383, 366	l by classification symbols)	
Documentati	on searched other than minimum documentation to the	ne extent that such documents are included	l in the fields searched
	ata base consulted during the international search (na continuation Sheet	me of data base and, where practicable, s	earch terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where a		Relevant to claim No.
Y	US 5,198,432 A(FARISS) 30 March 1993 (30.03.1	993), column 13, lines 10-25.	1-8
Y	ROBERTS et al. Prodrugs of L-Cysteine as Protec Induced Hepatotoxicuty. 2-(Polyhydroxyalkyl)-and carboxylic Acids. Journal of Medicinal Chemistry. 1896, especially abstract.	2-(Polyhydroxyalkyl)thiazolidine-4(r)-	1-8
Υ-	DILWORTH et al. Spntaneous Nitric Oxide in Heq Compound-Induced Apoptosis. Toxicology in Vitro pages 623-630, especialy abstact.		1-8
Y	POURAHMAD et al. A Comparison of Hepatocyte Cd2+. Toxicology. March 2000, Vol 143, No. 3,		1-8
Further	documents are listed in the continuation of Box C.	See patent family annex.	
* S	pecial categories of cited documents:	"T" later document published after the inter	
	defining the general state of the art which is not considered to be lar relevance	date and not in conflict with the application principle or theory underlying the investment	ntion
"E" carlier ap	plication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone	
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	
priority d	published prior to the international filling date but later than the ate claimed	"&" document member of the same patent f	
	ctual completion of the international search	Date of mailing of the international sear	ch report
	04 (19.03.2004) tiling address of the ISA/US	Authorized officer O	//
Mai Con	Istop PCT, Attn: ISA/US unissioner for Patents . Box 1450		berrisa
Alex	oandria, Virginia 223 13-1450 . (703)305-3230	Telephone No. 571/272-1600	U

Form PCT/ISA/210 (second sheet) (July 1998)

	PCT/US03/23869
INTERNATIONAL SEARCH REPORT	
•	1
	<u> </u>
•	
	•
•	
,	•
Continuation of B. FIELDS SEARCHED Item 3:	
WEST LIST DWDI-STN-BIOSIS CAPILIS MEDILINE	
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	tide, methylaraginine, oxo-thiazolidine .
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	side, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	kide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	kide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	kide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	kide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	kide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric ox	tide, methylaraginine, oxo-thiazolidine

Form PCT/ISA/210 (second sheet) (July 1998)